What is the clinical evidence from this study?

Study design: Other. Population: Rhino- and enterovirus infection. Intervention: TTP-8307. Primary outcome: Viral RNA synthesis inhibition and resistance mutations.

February 24, 2009Antimicrobial Agents and ChemotherapyOpen Access

Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307

View Full Paper

Ask AI

Bookmark

Key result

TTP-8307 inhibits viral RNA synthesis in rhino- and enteroviruses, with resistance conferred by mutations in the nonstructural protein 3A (V45A, I54F, and H57Y).

Authors

APArmando M. De PalmaRega Institute for Medical Research HTHendrik Jan ThibautRega Institute for Medical Research LLLonneke van der LindenAmsterdam UMC Location University of Amsterdam

Discussion

Member takes

Implication

Does not yet support clinical use; leaves open further development of 3A-targeted antivirals.

PICO

Population

Rhino- and enterovirus infection

Intervention / Comparator

TTP-8307

Primary Outcome

Viral RNA synthesis inhibition and resistance mutations

Cite This Study

Palma et al. (2009) studied Rhino- and enterovirus infection. TTP-8307 was evaluated on Viral RNA synthesis inhibition and resistance mutations. TTP-8307 inhibits viral RNA synthesis in rhino- and enteroviruses, with resistance conferred by mutations in the nonstructural protein 3A (V45A, I54F, and H57Y).

synapsesocial.com/papers/6a6c0a7847a1bfb288f36100 https://doi.org/10.1128/aac.00934-08

View Full Paper

Ask AI

Bookmark

Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307

Discussion

Member takes

Implication

PICO

Cite This Study

Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307

Discussion

Member takes

Implication

PICO

Cite This Study

Also Consider

Also Consider